How I assess comorbidities before hematopoietic cell transplantation

Blood

Volumn 121, Issue 15, 2013, Pages 2854-2863

  Sorror, Mohamed L ^a  

^a UNIVERSITY OF WASHINGTON SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CARDIOVASCULAR DISEASE; CEREBROVASCULAR DISEASE; CLINICAL ASSESSMENT; CLINICAL ASSESSMENT TOOL; CODING; COHORT ANALYSIS; COMORBIDITY; CONGESTIVE HEART FAILURE; CORONARY ARTERY DISEASE; DIABETES MELLITUS; DISEASE SEVERITY; EDUCATION PROGRAM; HEART ARRHYTHMIA; HEART EJECTION FRACTION; HEMATOPOIETIC CELL TRANSPLANTATION COMORBIDITY INDEX; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMAN; INFECTION; INFLAMMATORY BOWEL DISEASE; INFORMATION PROCESSING; KIDNEY DISEASE; LIVER DISEASE; LUNG DISEASE; MEDICAL EDUCATION; MEDICAL RECORD REVIEW; MENTAL DISEASE; NEOPLASM; OBESITY; OUTCOME ASSESSMENT; PATIENT ASSESSMENT; PEPTIC ULCER; PRACTICE GUIDELINE; PRIORITY JOURNAL; RHEUMATIC DISEASE; SCORING SYSTEM; VALIDATION STUDY; VALVULAR HEART DISEASE; CLINICAL CHEMISTRY; GRAFT VERSUS HOST REACTION; HEART DISEASE; MEDICAL RECORD; METHODOLOGY; PATHOPHYSIOLOGY; PREOPERATIVE PERIOD; REPRODUCIBILITY; RISK ASSESSMENT; STATISTICS;

CLINICAL CHEMISTRY TESTS; COMORBIDITY; GRAFT VS HOST DISEASE; GUIDELINES AS TOPIC; HEART DISEASES; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HUMANS; LIVER DISEASES; MEDICAL RECORDS; PREOPERATIVE PERIOD; REPRODUCIBILITY OF RESULTS; RISK ASSESSMENT;

MLCS; MLOWN;

EID: 84879441095     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2012-09-455063     Document Type: Article

References (41)

1. Feinstein AR. The pre-therapeutic classification of co-morbidity in chronic disease. J Chronic Dis. 1970;23(7):455-468.
2. Fried LP, Bandeen-Roche K, Kasper JD, et al. Association of comorbidity with disability in older women: The Women's Health and Aging Study. J Clin Epidemiol. 1999;52(1):27-37. (Pubitemid 29064271)
3. Jørgensen TL, Hallas J, Friis S, et al. Comorbidity in elderly cancer patients in relation to overall and cancer-specific mortality. Br J Cancer. 2012; 106(7):1353-1360.
4. van Spronsen DJ, Janssen-Heijnen ML, Breed WP, et al. Prevalence of co-morbidity and its relationship to treatment among unselected patients with Hodgkin's disease and non-Hodgkin's lymphoma, 1993-1996. Ann Hematol. 1999;78(7):315-319.
5. Sorror ML, Maris MB, Storb R, et al. Hematopoietic cell transplantation (HCT)-specific comorbidity index: A new tool for risk assessment before allogeneic HCT. Blood. 2005;106(8): 2912-2919. (Pubitemid 41510773)
6. Charlson ME, Pompei P, Ales KL, et al. A new method of classifying prognostic comorbidity in longitudinal studies: Development and validation. J Chronic Dis. 1987;40(5):373-383. (Pubitemid 17055592)
7. Sorror ML, Giralt S, Sandmaier BM, et al. Hematopoietic cell transplantation specific comorbidity index as an outcome predictor for patients with acute myeloid leukemia in first remission: Combined FHCRC and MDACC experiences. Blood. 2007; 110(13):4606-4613. (Pubitemid 351377830)
8. Maruyama D, Fukuda T, Kato R, et al. Comparable antileukemia/lymphoma effects in nonremission patients undergoing allogeneic hematopoietic cell transplantation with a conventional cytoreductive or reduced-intensity regimen. Biol Blood Marrow Transplant. 2007; 13(8):932-941. (Pubitemid 47055387)
9. Lim ZY, Ingram W, Brand R, et al. Impact of pretransplant comorbidities on alemtuzumab-based reduced-intensity conditioning allogeneic hematopoietic SCT for patients with high-risk myelodysplastic syndrome and AML. Bone Marrow Transplant. 2010;45(4):633-639.
10. Fujimaki K, Sakai R, Fujisawa S, et al. Usefulness of hematopoietic cell transplantation-specific comorbidity index after allogeneic hematopoietic stem cell transplantation [Japanese]. Gan To Kagaku Ryoho. 2008;35(1):87-91.
11. Majhail NS, Brunstein CG, Tomblyn M, et al. Reduced-intensity allogeneic transplant in patients older than 55 years: Unrelated umbilical cord blood is safe and effective for patients without a matched related donor. Biol Blood Marrow Transplant. 2008;14(3):282-289. (Pubitemid 351218198)
12. Boehm A, Sperr WR, Leitner G, et al. Comorbidity predicts survival in myelodysplastic syndromes or secondary acute myeloid leukaemia after allogeneic stem cell transplantation. Eur J Clin Invest. 2008;38(12):945-952.
13. Labonté L, Iqbal T, Zaidi MA, et al. Utility of comorbidity assessment in predicting transplantation-related toxicity following autologous hematopoietic stem cell transplantation for multiple myeloma. Biol Blood Marrow Transplant. 2008;14(9):1039-1044.
14. Pollack SM, Steinberg SM, Odom J, et al. Assessment of the hematopoietic cell transplantation comorbidity index in non-Hodgkin lymphoma patients receiving reduced-intensity allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2009;15(2):223-230.
15. Kataoka K, Nannya Y, Ueda K, et al. Differential prognostic impact of pretransplant comorbidity on transplant outcomes by disease status and time from transplant: A single Japanese transplant centre study. Bone Marrow Transplant. 2010; 45(3):513-520.
16. Barba P, Piñana JL, Martino R, et al. Comparison of two pretransplant predictive models and a flexible HCT-CI using different cut off points to determine low-, intermediate-, and high-risk groups: The flexible HCT-CI Is the best predictor of NRM and OS in a population of patients undergoing allo-RIC. Biol Blood Marrow Transplant. 2010;16(3):413-420.
17. Pavlů J, Kew AK, Taylor-Roberts B, et al. Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase. Blood. 2010;115(20):4018-4020.
18. Zipperer E, Pelz D, Nachtkamp K, et al. The hematopoietic stem cell transplantation comorbidity index is of prognostic relevance for patients with myelodysplastic syndrome. Haematologica. 2009;94(5):729-732.
19. Sperr WR, Wimazal F, Kundi M, et al. Comorbidity as prognostic variable in MDS: Comparative evaluation of the HCT-CI and CCI in a core dataset of 419 patients of the Austrian MDS Study Group. Ann Oncol. 2010;21(1):114-119.
20. Giles FJ, Borthakur G, Ravandi F, et al. The haematopoietic cell transplantation comorbidity index score is predictive of early death and survival in patients over 60 years of age receiving induction therapy for acute myeloid leukaemia. Br J Haematol. 2007;136(4):624-627. (Pubitemid 46148199)
21. Breccia M, Frustaci AM, Cannella L, et al. Comorbidities and FLT3-ITD abnormalities as independent prognostic indicators of survival in elderly acute myeloid leukaemia patients. Hematol Oncol. 2009;27(3):148-153.
22. Birninger N, Bornhäuser M, Schaich M, et al. The hematopoietic cell transplantation-specific comorbidity index fails to predict outcomes in high-risk AML patients undergoing allogeneic transplantation - investigation of potential limitations of the index. Biol Blood Marrow Transplant. 2011;17(12):1822-1832.
23. Sorror ML. Comorbidities and outcomes: Advancing the field comes at a price. Biol Blood Marrow Transplant. 2011;17(12):1721-1723.
24. Karnofsky DA, Burchenal JH. The clinical evaluation of chemotherapeutic agents in cancer. In: Macleod CM, ed. Evaluation of Chemotherapeutic Agents. New York: Columbia University Press; 1949:191-205.
25. Przepiorka D, Weisdorf D, Martin P, et al. 1994 Consensus conference on acute GVHD grading. Bone Marrow Transplant. 1995;15(6):825-828.
26. Cahn JY, Klein JP, Lee SJ, et al. Prospective evaluation of 2 acute graft-versus-host (GVHD) grading systems: A joint Société Française de Greffe de Moëlle et Thérapie Cellulaire (SFGM-TC), Dana Farber Cancer Institute (DFCI), and International Bone Marrow Transplant Registry (IBMTR) prospective study. Blood. 2005;106(4): 1495-1500. (Pubitemid 41129621)
27. Carpenter PA. How I conduct a comprehensive chronic graft-versus-host disease assessment. [Commentary] Blood. 2011;118(10):2679-2687.
28. Dinakara P, Blumenthal WS, Johnston RF, et al. The effect of anemia on pulmonary diffusing capacity with derivation of a correction equation. Am Rev Respir Dis. 1970;102(6):965-969.
29. Cotes JE, Dabbs JM, Elwood PC, et al. Iron-deficiency anaemia: Its effect on transfer factor for the lung (diffusiong capacity) and ventilation and cardiac frequency during sub-maximal exercise. Clin Sci. 1972;42(3):325-335.
30. Cohen J. A coefficient of agreement for nominal scales. Educ Psychol Meas. 1960;20(1):37-46.
31. Fleiss JL. Measuring nominal scale agreement among many raters. Psychol Bull. 1971;76(5): 378-382.
32. Streiner DL, Norman GR. Health Measurement Scales: A Practical Guide to Their Development. Oxford, United Kingdom: Oxford University Press; 2003.
33. Cohen J. Weighted kappa: Nominal scale agreement with provision for scaled disagreement or partial credit. Psychol Bull. 1968;70(4): 213-220.
34. Fleiss JL, Cohen J. The equivalence of weighted kappa and the intraclass correlation coefficient as measures of reliability. Educ Psychol Meas. 1973; 33(3):613-619.
35. Fleiss JL, Cohen J, Everitt BS. Large sample standard errors of kappa and weighted kappa. Psychol Bull. 1969;72(5):323-327.
36. Landis JR, Koch GG. The measurement of observer agreement for categorical data. Biometrics. 1977;33(1):159-174. (Pubitemid 8054849)
37. Hall SF, Groome PA, Streiner DL, et al. Interrater reliability of measurements of comorbid illness should be reported. J Clin Epidemiol. 2006;59(9): 926-933. (Pubitemid 44163422)
38. Imamura K, McKinnon M, Middleton R, et al. Reliability of a comorbidity measure: The Index of Co-Existent Disease (ICED). J Clin Epidemiol. 1997;50(9):1011-1016. (Pubitemid 27450361)
39. Liu M, Domen K, Chino N. Comorbidity measures for stroke outcome research: A preliminary study. Arch Phys Med Rehabil. 1997;78(2):166-172. (Pubitemid 27078677)
40. Extermann M, Overcash J, Lyman GH, et al. Comorbidity and functional status are independent in older cancer patients. J Clin Oncol. 1998;16(4):1582-1587. (Pubitemid 28175784)
41. Tuijn S, Janssens F, Robben P, et al. Reducing interrater variability and improving health care: A meta-analytical review. [Review] J Eval Clin Pract. 2012;18(4):887-895.